Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valganciclovir - Roche

Drug Profile

Valganciclovir - Roche

Alternative Names: Cymeval; R127; RG 127; RO 1079070/194; RS 079070194; RS 79070; TA-9070; Valcyte; Valgancyclovir; Valixa

Latest Information Update: 06 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Mitsubishi Tanabe Pharma Corporation; Roche; Stanford University School of Medicine; Vanderbilt University Medical Center
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus retinitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cytomegalovirus infections; Cytomegalovirus retinitis
  • No development reported Chronic fatigue syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 31 Aug 2018 Genentech and University of Utah initiates enrolment in the ValEAR phase III trial for Cytomegalovirus-infections (In infant) in USA (NCT03107871)
  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2018 Mitsubhishi Tanabe Pharma files a public knowledge-based application for treatment of paediatric organ transplan patients with Cytomegalovirus infections (Prevention) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top